Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
NCT00300781
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
136
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasms
Neoplasms
Interventions
DRUG:
neratinib
Sponsor
Puma Biotechnology, Inc.